PLSE · Pulse Biosciences

The thesis

Pulse Biosciences is modestly more likely to lead the S&P 500 over the next three months. The reason is cash: $189.2 million at 30 September 2026 funds its atrial-fibrillation (AF) catheter through pivotal follow-up and into regulatory filings. Two dated milestones test the case. The first is a persistent-AF study application guided for the fourth quarter of 2026. The second is one-year European data guided for the first quarter of 2027.

On 12 November 2026, at the Stifel 2026 Healthcare Conference, management set out its regulatory plan, as reported by Investing.com. It has started modular filings for both US and European approval. It plans to submit the clinical module, the last of five premarket approval (PMA) modules, to the Food and Drug Administration (FDA) in the third quarter of 2027. It expects FDA approval in early 2028 and the CE mark, the EU conformity certificate, in the second half of 2027. That matches the fourth-quarter 2027 CE-mark target in the 5 November 2026 third-quarter release.

The market has already priced in completed enrollment and the cash raise. The shares closed at $52.25 on 12 November 2026, up 17.3% over three months, and the 52-week closing low was $12.66 on 20 November 2025, per adjusted daily closes. Further gains need durability data or a partner, and neither has a confirmed date.

Bullish and bearish views on Pulse Biosciences, Inc

The bull case on Pulse Biosciences, Inc (PLSE), in brief: funding pressure has eased. The bear case: share sales continue.

Bull case

• Funding pressure has eased. Cash, equivalents and marketable securities were $189.2 million at 30 September 2026, up from $101.6 million at 30 June 2026, against third-quarter operating cash use of $15.3 million, per the 5 November 2026 release. On 12 November 2026, management said it aims to end 2026 with closer to $200 million, per Investing.com.
• Pivotal enrollment finished early. The third-quarter release reports 169 evaluable patients at 15 sites in NANOPULSE-AF, enrolled in under six months.
• The regulatory path now has dates. At Stifel on 12 November 2026, management guided a third-quarter 2027 PMA clinical-module submission and FDA approval in early 2028, per Investing.com.
• Thyroid data are positive. Six-month PRECISE-BTN results, presented at the American Thyroid Association meeting on 6 November 2026, showed 86% of patients reaching at least a 50% reduction in nodule volume and a median reduction of 72%. No serious adverse events were reported.
• Analysts raised targets after the report. On 6 November 2026, Canaccord Genuity raised its target to $74 from $58 and Needham raised its target to $64, both with Buy ratings.
• The chief operating officer bought shares. Liane Teplitsky bought 2,070 shares at an average $48.29 between 26 August 2026 and 28 August 2026, and 2,025 shares at an average $49.37 between 31 August 2026 and 1 September 2026, per SEC Form 4 filings.

Bear case

• Share sales continue. Shares outstanding rose to 73,314,797 at 30 September 2026 from 67,839,689 at 31 December 2025, per the third-quarter 10-Q. About $64 million of at-the-market (ATM) capacity remained, and the year-end cash goal of closer to $200 million, stated on 12 November 2026, points to more sales in the fourth quarter.
• Revenue missed. Third-quarter revenue of $395,000 fell short of the $516,667 estimate, and the net loss widened to $23.1 million from $19.4 million a year earlier, per the release and Benzinga. The cardiac program has no revenue.
• US approval is more than a year out. Management expects FDA approval in early 2028 and the CE mark in the second half of 2027, per its 12 November 2026 Stifel presentation.
• The surgical program is slower. NANOCLAMP-AF, the surgical-clamp AF study, is on track to finish enrollment only by the end of the first half of 2027, per the third-quarter release.
• Large competitors set the bar. Management cited Boston Scientific's FARAPULSE launch on 12 November 2026 as the model for a new entrant, which places the Pulse catheter against a system already selling at scale.

Price setup

The shares closed at $52.25 on 12 November 2026, down from $56.98 on 11 November 2026, in the session of the Stifel presentation. The highest close in the past year was $58.17 on 9 November 2026, and the 52-week intraday high was $58.94 in the same session. The last close is 11.4% below that high.

As of 12 November 2026, the 50-day moving average was $51.94 and the 200-day was $33.16, so the shares sit just above the 50-day average. Closes since the 5 November 2026 report have ranged from $52.25 on 12 November 2026 to $58.17 on 9 November 2026. The 3-month reference close was $44.54 on 14 August 2026.

The COO's open-market purchases at averages of $48.29 and $49.37 in late August sit below the current price. The close is below the Canaccord ($74) and Needham ($64) targets. The ATM program and the chairman's majority stake leave a thin tradable float, which widens daily moves in both directions.

Catalysts ahead

• ~31 December 2026 (est.): Guided fourth-quarter 2026 investigational device exemption (IDE) filing for a persistent atrial-fibrillation study. A filing on time, with study start early in 2027 as management described on 12 November 2026, extends the catheter beyond the current pivotal trial; a slip would be the first missed cardiac milestone since enrollment finished early.
• ~31 March 2027 (est.): One-year data from the 100-patient European feasibility study, guided for an AF conference in the first quarter of 2027. Durability of the arrhythmia result is the clinical question behind any partnership and the second-half 2027 CE-mark target.
• ~30 September 2027 (est.): Planned FDA submission of the final PMA clinical module, guided for the third quarter of 2027. On-time submission keeps the early-2028 US approval target intact; a delay pushes back first US cardiac revenue.

What would change the view

A daily close below $48.00, under the 50-day moving average and every close since the 5 November 2026 report, which would show the post-enrollment gains failing. A change to the NANOPULSE-AF pivotal design, a CE-mark target later than the fourth quarter of 2027 or an FDA approval target later than early 2028 would also break the case.

The risks this note tracks, each with what would confirm it:

• Equity issuance continues into strength and caps the share price. Confirmed by: fourth-quarter 2026 filings showing most of the roughly $64 million remaining ATM capacity used, or a new larger offering before pivotal data.
• The European approval timeline slips, delaying first cardiac revenue. Confirmed by: a CE-mark target later than the fourth quarter of 2027 in a company release or call.
• The US approval path slips. Confirmed by: the PMA clinical module moved past the third quarter of 2027, or an FDA approval target later than early 2028.
• The persistent-AF program falls behind its guided schedule. Confirmed by: no IDE submission for a persistent-AF study disclosed with the fourth-quarter 2026 results.
• Safety or protocol problems surface during pivotal follow-up. Confirmed by: a disclosed site suspension, a change to the NANOPULSE-AF design, or a delay to the 6- or 12-month endpoint assessment.
• European durability data disappoint. Confirmed by: one-year feasibility results in the first quarter of 2027 showing arrhythmia recurrence materially above results reported for approved pulsed field ablation systems.
• The partnership path stalls, leaving Pulse to fund commercialization alone. Confirmed by: no named partner by the time pivotal data are presented, alongside a further equity raise.

What it trades with

Pulse trades with small-cap medical-device and clinical-stage names, where financing conditions and rate expectations often move shares more than company news. Its catheter competes in pulsed field ablation, a field led by Boston Scientific, Medtronic, Abbott and Johnson & Johnson, so their data, approvals and share shifts move sentiment. Management told the Stifel audience on 12 November 2026 that its "principal strategy is to prepare for a strategic partnership," which ties the valuation to interest from those larger companies. Share sales through the ATM program link the share price to the company's own funding decisions.